Drugmaker Shire bids $30 billion for Baxter spin-off Baxalta
0
LONDON (Reuters) - Drugmaker Shire said on Tuesday it was seeking to buy Baxalta , a company spun-off by Baxter International last month, for $30 billion (£19.2 billion) to forge the leading global specialist in rare diseases.